CTIS2023-508439-30-00进行中（未招募）1 期
NXPTEGO/23/P1-4
euraxpharm Pharmaceuticals S.L.0 个研究点目标入组 210 人开始时间: 2023年12月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-00Helsinn Healthcare S.A.74
进行中（未招募）
1 期
Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid TumorsMetastatic Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-503425-18-00F. Hoffmann-La Roche AG192
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditionsCTIS2023-503557-35-00Alter Farmacia S.A.24
进行中（未招募）
1 期
Bioequivalence clinical trial of two formulations of Pregabalin 300 mg.Healthy volunteersCTIS2022-501160-18-00aboratorios Normon S.A.24